MCA
NBIX icon

Maryland Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Maryland Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169 Buy
+1
New +$148 ﹤0.01% 503

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Maryland Capital Advisors's NBIX Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1 share worth $169. The stake represents ﹤0.01% of the portfolio and ranks #503 among its holdings.

771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Maryland Capital Advisors held 1 share of Neurocrine Biosciences worth $169 as of Q2 2026.
  • Neurocrine Biosciences was a new Maryland Capital Advisors position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #503 holding.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.